Virologica Sinica

, Volume 29, Issue 1, pp 25–32 | Cite as

Ficolins and infectious diseases

Review

Abstract

Ficolins are serum complement lectins, with a structure similar to mannose-binding lectin (MBL) and lung surfactant protein (SP)-A and SP-D. Ficolins activate the lectin complement system and play important roles in host innate immunity. Ficolins are members of the collectin family of proteins, which act as pattern recognition receptors (PRRs). They are soluble oligomeric defense proteins with lectin-like activity, and are able to recognize pathogen-associated molecular patterns (PAMPs), which are carbohydrate molecules on the surface of pathogens, and of apoptotic, necrotic, and malignant cells. Upon binding to their specific PAMPs, ficolins may trigger activation of the immune system either (1) by initiating activation of complement via the lectin pathway, (2) by a primitive type of opsonophagocytosis, or (3) by stimulating secretion of the inflammatory cytokines interferon (IFN)-Γ, interleukin (IL)-17, IL-6, and tumor necrosis factor (TNF)-α, and production of nitric oxide (NO) by macrophages, thus limiting the infection and concurrently orchestrating the subsequent adaptive immune response. Recently, a number of reports have shown that dysfunction or abnormal expression of ficolins may play crucial roles in viral and bacterial diseases and in inflammation. This review summarizes the reports on the roles of ficolins in the infectious diseases, and provides insight into ficolins as novel innate immune therapeutic options to treat these diseases.

Keywords

L-ficolin H-ficolin M-ficolin virus bacteria 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akaiwa M, Yae Y, Sugimoto R, Suzuki S O, Iwaki T, Izuhara K, and Hamasaki N. 1999. Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J Histochem Cytochem, 47: 777–786.PubMedCrossRefGoogle Scholar
  2. Ammitzboll C G, Thiel S, Ellingsen T, Deleuran B, Jorgensen A, Jensenius J C, and Stengaard-Pedersen K. 2012. Levels of lectin pathway proteins in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis. Rheumatol Int, 32: 1457–1463.PubMedCrossRefGoogle Scholar
  3. Aoyagi Y, Adderson E E, Min J G, Matsushita M, Fujita T, Takahashi S, Okuwaki Y, and Bohnsack J F. 2005. Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci. J Immunol, 174: 418–425.PubMedGoogle Scholar
  4. Chang W C, Hartshorn K L, White M R, Moyo P, Michelow I C, Koziel H, Kinane B T, Schmidt E V, Fujita T, and Takahashi K. 2011. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem Pharmacol, 81: 388–395.PubMedCentralPubMedCrossRefGoogle Scholar
  5. Dommett R M, Klein N, and Turner M W. 2006. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens, 68: 193–209.PubMedCrossRefGoogle Scholar
  6. Egli A, Schafer J, Osthoff M, Thiel S, Mikkelsen C, Rauch A, Hirsch H H, Bucher H C, Young J, Jensenius J C, Battegay M, and Trendelenburg M. 2013. Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One, 8: e51983.PubMedCentralPubMedCrossRefGoogle Scholar
  7. Endo Y, Matsushita M, and Fujita T. 2011. The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol, 43: 705–712.PubMedCrossRefGoogle Scholar
  8. Endo Y, Sato Y, Matsushita M, and Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515–521.PubMedCrossRefGoogle Scholar
  9. Frederiksen P D, Thiel S, Larsen C B, and Jensenius J C. 2005. M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand J Immunol, 62: 462–473.PubMedCrossRefGoogle Scholar
  10. Fujimori Y, Harumiya S, Fukumoto Y, Miura Y, Yagasaki K, Tachikawa H, and Fujimoto D. 1998. Molecular cloning and characterization of mouse ficolin-A. Biochem Biophys Res Commun, 244: 796–800.PubMedCrossRefGoogle Scholar
  11. Gokudan S, Muta T, Tsuda R, Koori K, Kawahara T, Seki N, Mizunoe Y, Wai S N, Iwanaga S, and Kawabata S. 1999. Horseshoe crab acetyl group-recognizing lectins involved in innate immunity are structurally related to fibrinogen. Proc Natl Acad Sci U S A, 96: 10086–10091.PubMedCentralPubMedCrossRefGoogle Scholar
  12. Hoang T V, Toan N L, Songle H, Ouf E A, Bock C T, Kremsner P G, Kun J F, and Velavan T P. 2011. Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One, 6: e28113.PubMedCrossRefGoogle Scholar
  13. Holmskov U, Thiel S, and Jensenius J C. 2003. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol, 21: 547–578.PubMedCrossRefGoogle Scholar
  14. Hu Y L, Luo F L, Fu J L, Chen T L, Wu S M, Zhou Y D, and Zhang X L. 2013. Early increased ficolin-2 oncentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol, 77: 144–150.PubMedCrossRefGoogle Scholar
  15. Ichijo H, Hellman U, Wernstedt C, Gonez L J, Claesson-Welsh L, Heldin C H, and Miyazono K. 1993. Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. J Biol Chem, 268: 14505–14513.PubMedGoogle Scholar
  16. Jack D L, Dodds A W, Anwar N, Ison C A, Law A, Frosch M, Turner M W, and Klein N J. 1998. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol, 160: 1346–1353.PubMedGoogle Scholar
  17. Keirstead N D, Lee C, Yoo D, Brooks A S, and Hayes M A. 2008. Porcine plasma ficolin binds and reduces infectivity of porcine reproductive and respiratory syndrome virus (PRRSV) in vitro. Antiviral Res, 77: 28–38.PubMedCrossRefGoogle Scholar
  18. Kilpatrick D C, and Chalmers J D. 2012. Human L-ficolin (ficolin-2) and its clinical significance. J Biomed Biotechnol, 2012: 138797.PubMedCentralPubMedCrossRefGoogle Scholar
  19. Kilpatrick D C, Chalmers J D, MacDonald S L, Murray M, Mohammed A, Hart S P, Matsushita M, and Hill A. 2009. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J, 3: 29–33.PubMedCrossRefGoogle Scholar
  20. Kjaer T R, Hansen A G, Sorensen U B, Nielsen O, Thiel S, and Jensenius J C. 2011. Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J Leukoc Biol, 90: 425–437.PubMedCrossRefGoogle Scholar
  21. Liu J, Ali M A, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, and Zhang X. 2009. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235–244.PubMedCrossRefGoogle Scholar
  22. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, and Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 175: 3150–3156.PubMedGoogle Scholar
  23. Lu J, Tay P N, Kon O L, and Reid K B. 1996. Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9. Biochem J, 313( Pt 2): 473–478.PubMedGoogle Scholar
  24. Luo F, Sun X, Wang Y, Wang Q, Wu Y, Pan Q, Fang C, and Zhang X L. 2013. Ficolin-2 defends against virulent Mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS One, 8: e73859.PubMedCentralPubMedCrossRefGoogle Scholar
  25. Lynch N J, Roscher S, Hartung T, Morath S, Matsushita M, Maennel D N, Kuraya M, Fujita T, and Schwaeble W J. 2004. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol, 172: 1198–1202.PubMedGoogle Scholar
  26. Matsushita M. 2010. Ficolins: complement-activating lectins involved in innate immunity. J Innate Immun, 2: 24–32.PubMedCrossRefGoogle Scholar
  27. Matsushita M, Endo Y, and Fujita T. 2000. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol, 164: 2281–2284.PubMedGoogle Scholar
  28. Matsushita M, Endo Y, Hamasaki N, and Fujita T. 2001. Activation of the lectin complement pathway by ficolins. Int Immunopharmacol, 1: 359–363.PubMedCrossRefGoogle Scholar
  29. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, and Mizuochi T. 1996. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448–2454.PubMedCrossRefGoogle Scholar
  30. Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature, 449: 819–826.PubMedCrossRefGoogle Scholar
  31. Medzhitov R, and Janeway C A, Jr. 2002. Decoding the patterns of self and nonself by the innate immune system. Science, 296: 298–300.PubMedCrossRefGoogle Scholar
  32. Michelow I C, Dong M, Mungall B A, Yantosca L M, Lear C, Ji X, Karpel M, Rootes C L, Brudner M, Houen G, Eisen D P, Kinane T B, Takahashi K, Stahl G L, Olinger G G, Spear G T, Ezekowitz R A, and Schmidt E V. 2010. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem, 285: 24729–24739.PubMedCrossRefGoogle Scholar
  33. Munthe-Fog L, Hummelshoj T, Honore C, Madsen H O, Permin H, and Garred P. 2009. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med, 360: 2637–2644.PubMedCrossRefGoogle Scholar
  34. Nahid A M, and Sugii S. 2006. Binding of porcine ficolin-alpha to lipopolysaccharides from Gram-negative bacteria and lipoteichoic acids from Gram-positive bacteria. Dev Comp Immunol, 30: 335–343.PubMedCrossRefGoogle Scholar
  35. Pan Q, Chen H, Wang F, Jeza V T, Hou W, Zhao Y, Xiang T, Zhu Y, Endo Y, Fujita T, and Zhang X L. 2012. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun, 4: 312–324.PubMedCrossRefGoogle Scholar
  36. Rorvig S, Honore C, Larsson L I, Ohlsson S, Pedersen C C, Jacobsen L C, Cowland J B, Garred P, and Borregaard N. 2009. Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. J Leukoc Biol, 86: 1439–1449.PubMedCrossRefGoogle Scholar
  37. Schaffer T, Flogerzi B, Schoepfer A M, Seibold F, and Muller S. 2013. Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease patients with reduced H-ficolin levels but normal MASP-2 activity. J Crohns Colitis, 7: e1–10.PubMedCrossRefGoogle Scholar
  38. Schlapbach L J, Aebi C, Hansen A G, Hirt A, Jensenius J C, and Ammann R A. 2009. H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin Exp Immunol, 157: 83–89.PubMedCentralPubMedCrossRefGoogle Scholar
  39. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, and Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721–20727.PubMedCrossRefGoogle Scholar
  40. Taira S, Kodama N, Matsushita M, and Fujita T. 2000. Opsonic function and concentration of human serum ficolin/P35. Fukushima J Med Sci, 46: 13–23.PubMedCrossRefGoogle Scholar
  41. Takahashi K, Moyo P, Chigweshe L, Chang W C, White M R, and Hartshorn K L. 2013. Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res, 178: 495–501.PubMedCrossRefGoogle Scholar
  42. Teh C, Le Y, Lee S H, and Lu J. 2000. M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli. Immunology, 101: 225–232.PubMedCrossRefGoogle Scholar
  43. Tsujimura M, Ishida C, Sagara Y, Miyazaki T, Murakami K, Shiraki H, Okochi K, and Maeda Y. 2001. Detection of serum thermolabile beta-2 macroglycoprotein (Hakata antigen) by enzyme-linked immunosorbent assay using polysaccharide produced by Aerococcus viridans. Clin Diagn Lab Immunol, 8: 454–459.PubMedCentralPubMedGoogle Scholar
  44. Verma A, White M, Vathipadiekal V, Tripathi S, Mbianda J, Ieong M, Qi L, Taubenberger J K, Takahashi K, Jensenius J C, Thiel S, and Hartshorn K L. 2012. Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J Immunol, 189: 2478–2487.PubMedCentralPubMedCrossRefGoogle Scholar
  45. Wang C C, Yim K W, Poon T C, Choy K W, Chu C Y, Lui W T, Lau T K, Rogers M S, and Leung T N. 2007. Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem, 53: 42–52.PubMedCrossRefGoogle Scholar
  46. Zhang X L, and Ali M A. 2008. Ficolins: structure, function and associated diseases. Adv Exp Med Biol, 632: 105–115.PubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.State Key Laboratory of Virology and Department of Immunology and Hubei Province Key Laboratory of Allergy and ImmunologyWuhan University School of MedicineWuhanChina

Personalised recommendations